AnaptysBio, Inc. Forecast, price target & analysts
AnaptysBio, Inc. Target price 2026 - Analyst rating & recommendation
AnaptysBio, Inc. Classifications & Recommendation
AnaptysBio, Inc. Price Target
| Target Price | $84.66 |
| Price | $51.70 |
| Potential |
63.75%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target AnaptysBio, Inc. 2027 .
The average AnaptysBio, Inc. target price is $84.66.
This is
63.75%
register free of charge
$147.00
184.33%
register free of charge
$70.70
36.75%
register free of charge
|
|
| A rating was issued by 17 analysts: 16 Analysts recommend AnaptysBio, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AnaptysBio, Inc. stock has an average upside potential 2027 of
63.75%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 234.60 | 156.24 |
| 157.01% | 33.40% | |
| EBITDA Margin | 20.66% | 73.73% |
| 116.49% | 256.93% | |
| Net Margin | -5.64% | -20.06% |
| 96.46% | 255.71% |
11 Analysts have issued a sales forecast AnaptysBio, Inc. 2026 . The average AnaptysBio, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an AnaptysBio, Inc. EBITDA forecast 2026. The average AnaptysBio, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 AnaptysBio, Inc. Analysts have issued a net profit forecast 2026. The average AnaptysBio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.46 | -1.08 |
| 91.02% | 134.78% | |
| P/E | negative | |
| EV/Sales | 9.57 |
13 Analysts have issued a AnaptysBio, Inc. forecast for earnings per share. The average AnaptysBio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
AnaptysBio, Inc....
Current AnaptysBio, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 24 2026 |
| UBS |
Locked
➜
Locked
|
Locked | May 13 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | May 13 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 04 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Apr 28 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Apr 22 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 24 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
May 13 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 13 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 04 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Apr 28 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Apr 22 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
